Exhibit 99.1
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2023 RESULTS
Minneapolis/November 1, 2022/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2022.
First Quarter FY2023 Highlights
| ● | First quarter organic revenue increased by 7% (5% reported) to $269.7 million. |
| ● | GAAP EPS was $2.21 versus $1.69 one year ago. Current year adjusted earnings per share (EPS) of $1.78 was negatively impacted by $0.12 of unfavorable foreign currency exchange when compared to prior year adjusted earnings per share of $1.83. |
| ● | Diagnostics and Genomics achieved 17% organic growth with strong execution across its entire portfolio. |
| ● | Delivered operating cash flow of $56.1 million, an increase of 16% when compared to the prior year. |
| ● | Continued acceleration of the ExoDx Prostate test resulting in a third consecutive record quarter, as tests performed grew over 70% and revenue increased over 100% year-over-year. |
The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). Adjusted diluted EPS, adjusted earnings, adjusted gross margin, adjusted operating income, adjusted tax rate, organic growth, and adjusted operating margin are non-GAAP measures that exclude certain items detailed later in this press release under the heading “Use of non-GAAP Adjusted Financial Measures.” A reconciliation of GAAP to non-GAAP financial measures is included in this press release.
“I am very pleased with the performance of the Diagnostics and Genomics segment (D&GS), which helped offset the tough year-over-year comparisons we faced in our Protein Sciences segment in Europe and China,” said Chuck Kummeth, President and CEO of Bio-Techne. “In D&GS, we saw increased traction across our portfolio of Spatial Biology solutions, ramping ExoDx Prostate test volume, increased adoption of our Asuragen genetic carrier screening kits, and strength in our Diagnostics Reagents business which led to 17% organic segment growth. For ExoDx Prostate, we delivered a third consecutive record test volume quarter, as year over year test volume increased over 70% and revenue grew over 100% for the quarter. With increasing doctor ordering patterns and a growing base of new physicians ordering the test, I believe fiscal 2023 will be a breakout year for ExoDx Prostate.”
Kummeth continued, “Long-term, we remain incredibly well positioned and under penetrated in some of the highest growth life science tools and diagnostic end markets. Our leading portfolio of proteomic research reagents and analytical tools, cell and gene therapy workflow solutions, spatial biology products, liquid biopsy technologies and diagnostic reagents position Bio-Techne to successfully penetrate these markets. We will continue to execute our strategic growth plan, manage through any shorter-term regional economic turbulence, and create value for our stakeholders.”
First Quarter Fiscal 2023
Revenue
Net sales for the first quarter increased 5% to $269.7 million. Organic growth was 7% compared to the prior year, with acquisitions contributing 1% and foreign currency exchange having an unfavorable impact of 3%.
GAAP Earnings Results
GAAP EPS was $2.21 per diluted share, versus $1.69 in the same quarter last year. GAAP EPS was positively impacted in the current year by a gain on the sale of our ChemoCentryx investment and a gain on the sale of our Eminence investment, a partially-owned consolidated subsidiary. GAAP operating income for the first quarter of fiscal 2023 decreased 11% to $56.3 million, compared to $63.2 million in the first quarter of fiscal 2022. GAAP operating margin was 20.9%, compared to 24.5% in the first quarter of fiscal 2022. GAAP operating margin compared to prior year was negatively impacted by foreign currency impacts, year-over-year changes in acquisition related expenses, and unfavorable product mix.
Non-GAAP Earnings Results
Adjusted EPS was $1.78 per diluted share, versus $1.83 in the same quarter last year, a decrease of 3%. Adjusted EPS was negatively impacted by $0.12 due to unfavorable foreign currency exchange, which was partially offset by revenue growth. Adjusted operating income for the first quarter of fiscal 2023 decreased 4% compared to the first quarter of fiscal 2022. Adjusted operating margin was 34.8%, compared to 37.8% in the first quarter of fiscal 2022. Adjusted operating margin decreased compared to the prior year due to unfavorable foreign currency exchange and timing of strategic growth investments, including the acquisition of Namocell.
Segment Results
Management uses adjusted operating results to monitor and evaluate performance of the Company’s business segments, as highlighted below.
Protein Sciences Segment
The Company’s Protein Sciences segment is one of the world’s leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology and academic research communities. Additionally, the segment provides an array of platforms useful in various areas of protein analysis. Protein Sciences segment’s first quarter fiscal 2023 net sales were $199.9 million, an increase of 1% from $197.2 million for the first quarter of fiscal 2022. Organic growth for the segment was 3%, with acquisitions contributing 1% and foreign currency exchange having an unfavorable impact of 3%. Protein Sciences segment’s operating margin was 43.0% in the first quarter of fiscal 2023 compared to 45.7% in the first quarter of fiscal 2022. The segment’s operating margin compared to the prior year was negatively impacted by unfavorable foreign currency exchange, timing of strategic growth investments, and acquisitions.
Diagnostics and Genomics Segment
The Company’s Diagnostics and Genomics segment provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Genomics segment also develops and provides in situ hybridization products as well as exosome-based diagnostics for various pathologies, including prostate cancer. The Diagnostics and Genomics segment’s first quarter fiscal 2023 net sales were $69.9 million, an increase of 15% from $61.0 million for the first quarter of fiscal 2022. Organic growth for the segment was 17%, with foreign currency exchange having an unfavorable 2% impact. The Diagnostics and Genomics segment’s operating margin was 12.4% in the first quarter of fiscal 2023 compared to 12.2% in the first quarter of fiscal 2022. The segment’s operating margin was positively impacted by volume leverage, which was partially offset by unfavorable foreign currency exchange.
Conference Call
Bio-Techne will host an earnings conference call today, November 1, 2022 at 8:00 a.m. CDT. To listen, please dial 1-877-407-9208 or 1-201-493-6784 for international callers, and reference conference ID 13733551. The earnings call can also be accessed via webcast through the following link https://investors.bio-techne.com/ir-calendar.
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512- 2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13733551. The replay will be available from 11:00 a.m. CDT on Tuesday, November 1, 2022 until 11:00 p.m. CST on Thursday, December 1, 2022.
Use of non-GAAP Adjusted Financial Measures:
This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:
· | Organic growth |
· | Adjusted diluted earnings per share |
· | Adjusted earnings |
· | Adjusted tax rate |
· | Adjusted gross margin |
· | Adjusted operating income |
· | Adjusted operating margin |
· Earnings before interest, taxes, depreciation, and amortization (EBITDA)
· Adjusted EBITDA
We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.
Our non-GAAP financial measure of organic growth represents revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, as well as the impact of partially-owned consolidated subsidiaries. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from partially-owned subsidiaries consolidated in our financial statements are also excluded from our organic revenue calculation, as those revenues are not fully attributable to the Company. Revenue from partially-owned consolidated subsidiaries was $2.0 million for the quarter ended September 30, 2022.
Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including non-recurring costs, goodwill and long-lived asset impairments, and gains. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjection assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory and acquisition-related expenses inclusive of the changes in fair value contingent consideration, and other non-recurring items including gains or losses on legal settlements, goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to partially-owned consolidated subsidiaries in the calculation of our non-GAAP financial measures as the revenues and expenses are not fully attributable to the Company.
The Company’s non-GAAP adjusted operating margin and adjusted net earnings, in total and on a per share basis, also excludes stock-based compensation expense, which is inclusive of the employer portion of payroll taxes on those stock awards, restructuring, impairments of equity method investments, gain and losses from investments, and certain adjustments to income tax expense.
Impairments of equity investments are excluded as they are not part of our day-to-day operating decisions. Additionally, gains and losses from other investments that are either isolated or cannot be expected to occur again with any predictability are excluded.
Costs related to restructuring activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of
operating results and not necessarily reflect costs and/or income associated with historical trends and future results.
Investors are encouraged to review the reconciliations of adjusted financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.
Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company’s actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company’s customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues resulting from the COVID-19 pandemic, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the section titled “Risk Factors” in the Company’s annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio techne.com.
Contact: | David Clair, Vice President, Investor Relations |
David.Clair@bio-techne.com
612-656-4416
BIO-TECHNE CORPORATION
CONSOLIDATED STATEMENTS OF EARNINGS
(In thousands, except per share data)
(Unaudited)
| | QUARTER | ||||
| | ENDED | ||||
|
| 9/30/2022 |
| 9/30/2021 | ||
Net sales | | $ | 269,655 | | $ | 257,719 |
Cost of sales | |
| 90,060 | |
| 86,722 |
Gross margin | |
| 179,595 | |
| 170,997 |
Operating expenses: | |
| | |
|
|
Selling, general and administrative | |
| 99,375 | |
| 86,175 |
Research and development | |
| 23,903 | |
| 21,600 |
Total operating expenses | |
| 123,278 | |
| 107,775 |
Operating income | |
| 56,317 | |
| 63,222 |
Other income (expense) | |
| 47,399 | |
| 4,161 |
Earnings before income taxes | |
| 103,716 | |
| 67,383 |
Income taxes | |
| 13,982 | |
| (1,598) |
Net earnings, including noncontrolling interest | | $ | 89,734 | | $ | 68,981 |
Net earnings (loss) attributable to noncontrolling interest | |
| 179 | |
| (634) |
Net earnings attributable to Bio-Techne | |
| 89,555 | |
| 69,615 |
Earnings per share: | |
|
| |
|
|
Basic | | $ | 2.28 | | $ | 1.78 |
Diluted | | $ | 2.21 | | $ | 1.69 |
Weighted average common shares outstanding | | | | | | |
Basic | |
| 39,232 | |
| 39,094 |
Diluted | |
| 40,543 | |
| 41,158 |
BIO-TECHNE CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(In thousands)
(Unaudited)
|
| 9/30/2022 |
| 6/30/2022 | ||
ASSETS | |
| | |
| |
Cash and equivalents | | $ | 165,257 | | $ | 172,567 |
Short-term available-for-sale investments | |
| 37,818 | |
| 74,462 |
Accounts receivable, net | |
| 174,174 | |
| 194,548 |
Inventories | |
| 150,009 | |
| 141,123 |
Other current assets | |
| 24,773 | |
| 22,856 |
Total current assets | |
| 552,031 | |
| 605,556 |
| | | | | | |
Property and equipment, net | |
| 224,098 | |
| 223,242 |
Right of use asset | |
| 69,745 | |
| 65,556 |
Goodwill and intangible assets, net | |
| 1,450,952 | |
| 1,353,623 |
Other assets | |
| 53,895 | |
| 46,828 |
Total assets | | $ | 2,350,721 | | $ | 2,294,805 |
| | | | | | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |
|
| |
|
|
Accounts payable and accrued expenses | | $ | 76,822 | | $ | 113,704 |
Contract liabilities | |
| 22,059 | |
| 23,406 |
Income taxes payable | |
| 17,270 | |
| 13,237 |
Contingent consideration payable | |
| 7,400 | |
| — |
Operating lease liabilities - current | |
| 12,115 | |
| 11,928 |
Current portion of long-term debt obligations | |
| — | |
| 12,500 |
Other current liabilities | |
| 1,963 | |
| 1,243 |
Total current liabilities | |
| 137,629 | |
| 176,018 |
| | | | | | |
Deferred income taxes | |
| 112,920 | |
| 98,994 |
Long-term debt obligations | |
| 264,661 | |
| 243,410 |
Operating lease liabilities | |
| 64,756 | |
| 58,133 |
Long-term contingent consideration payable | |
| 8,100 | |
| 5,000 |
Other long-term liabilities | |
| 11,501 | |
| 12,239 |
Stockholders' equity | |
| 1,751,154 | |
| 1,701,011 |
Total liabilities and stockholders' equity | | $ | 2,350,721 | | $ | 2,294,805 |
BIO-TECHNE CORPORATION
RECONCILIATION OF ADJUSTED GROSS MARGIN PERCENTAGE
(Unaudited)
| | QUARTER | ||||
| | ENDED | ||||
| | 9/30/2022 | | 9/30/2021 | ||
Gross margin percentage - GAAP |
| 66.6 | % | | 66.4 | % |
Identified adjustments: |
|
|
| |
|
|
Costs recognized upon sale of acquired inventory |
| 0.1 | % | | 0.6 | % |
Amortization of intangibles |
| 4.1 | % | | 4.0 | % |
Stock-based compensation, inclusive of employer taxes |
| 0.1 | % | | 0.1 | % |
Impact of partially-owned consolidated subsidiaries(1) |
| 0.0 | % | | 0.1 | % |
Gross margin percentage - Adjusted |
| 70.9 | % | | 71.2 | % |
1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party.
BIO-TECHNE CORPORATION
RECONCILIATION OF ADJUSTED OPERATING MARGIN PERCENTAGE
(Unaudited)
| | QUARTER | ||||
| | ENDED | ||||
|
| 9/30/2022 |
| 9/30/2021 | ||
Operating margin percentage - GAAP |
| 20.9 | % | | 24.5 | % |
Identified adjustments: |
|
|
| |
|
|
Costs recognized upon sale of acquired inventory |
| 0.1 | % | | 0.6 | % |
Amortization of intangibles |
| 7.2 | % | | 7.1 | % |
Acquisition related expenses |
| 0.1 | % | | (0.9) | % |
Stock-based compensation, inclusive of employer taxes |
| 5.8 | % | | 5.4 | % |
Restructuring costs |
| 0.8 | % | | 0.5 | % |
Impact of partially owned-consolidated subsidiaries(1) |
| (0.1) | % | | 0.6 | % |
Operating margin percentage - Adjusted |
| 34.8 | % | | 37.8 | % |
1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party. As disclosed in our use of Non-GAAP Adjusted Financial Measures, the adjusted operating margin percentages excludes partially-owned consolidated revenue and expense amounts. The excluded revenue attributable to partially-owned consolidated subsidiaries impacted the operating margin by (0.3%) for the first quarter of fiscal 2023, and 0.6% for the comparative prior year. The excluded operating (income)/loss impacted the operating margin by 0.2% for the first quarter of fiscal 2023, and did not materially impact the first quarter of fiscal 2022.
BIO-TECHNE CORPORATION
NON-GAAP ADJUSTED CONOLIDATED NET EARNINGS and EARNINGS per SHARE
(In thousands, except per share data) (Unaudited)
| | QUARTER | |||||
| | ENDED | |||||
|
| 9/30/2022 | | 9/30/2021 | |||
Net earnings before taxes- GAAP |
| $ | 103,716 | | $ | 67,383 | |
Identified adjustments attributable to Bio-Techne: | |
| | | | | |
Costs recognized upon sale of acquired inventory | | | 300 | |
| 1,512 | |
Amortization of intangibles | |
| 19,283 | |
| 18,389 | |
Acquisition related expenses | |
| 678 | |
| (2,262) | |
Gain on sale of partially owned consolidated subsidiaries | |
| (11,682) | |
| — | |
Stock-based compensation, inclusive of employer taxes | |
| 15,458 | |
| 13,860 | |
Restructuring costs | |
| 2,170 | |
| 1,185 | |
Investment (gain) loss and other | |
| (38,087) | |
| (6,235) | |
Impact of partially-owned consolidated subsidiaries(1) | |
| (420) | |
| 1,562 | |
Net earnings before taxes - Adjusted(1) | | $ | 91,416 | | $ | 95,394 | |
Non-GAAP tax rate | |
| 21.0 | % |
| 21.0 | % |
Non-GAAP tax expense | | | 19,197 | | | 20,033 | |
Non-GAAP adjusted net earnings attributable to Bio-Techne(1) | | $ | 72,219 | | $ | 75,361 | |
Earnings per share - diluted - Adjusted(1) | | $ | 1.78 | | $ | 1.83 | |
1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party.
BIO-TECHNE CORPORATION
NON-GAAP ADJUSTED TAX RATE (In percentages)
(Unaudited)
| | QUARTER | ||||
| | ENDED | ||||
|
| 9/30/2022 | | 9/30/2021 | ||
GAAP effective tax rate |
| 13.5 | % | | (2.4) | % |
Discrete items | | 8.4 | % | | 26.3 | % |
Impact of non-taxable net gain |
| 1.6 | % | | — | % |
Long-term GAAP tax rate |
| 23.5 | % | | 23.9 | % |
Rate impact items | | | | | | |
Stock based compensation |
| (3.1) | % | | (2.1) | % |
Other | | 0.6 | % | | (0.8) | % |
Total rate impact items |
| (2.5) | % | | (2.9) | % |
Non-GAAP adjusted tax rate |
| 21.0 | % | | 21.0 | % |
BIO-TECHNE CORPORATION
SEGMENT REVENUE
(In thousands)
(Unaudited)
| | QUARTER | ||||
| | ENDED | ||||
|
| 9/30/2022 |
| 9/30/2021 | ||
Protein Sciences segment revenue | | $ | 199,949 | | $ | 197,186 |
Diagnostics and Genomics segment revenue | |
| 69,904 | |
| 60,985 |
lntersegment revenue | |
| (198) | |
| (452) |
Consolidated revenue | | $ | 269,655 | | $ | 257,719 |
BIO-TECHNE CORPORATTON
SEGMENT OPERATING INCOME
(In thousands)
(Unaudited)
| | QUARTER | ||||
| | ENDED | ||||
|
| 9/30/2022 |
| 9/30/2021 | ||
Protein Sciences segment operating income | | $ | 85,942 |
| $ | 90,100 |
Diagnostics and Genomics segment operating income | |
| 8,638 |
| | 7,463 |
Segment operating income | |
| 94,580 | |
| 97,563 |
Corporate general, selling, and administrative | |
| (1,402) | |
| (210) |
Adjusted operating income | |
| 93,178 | |
| 97,353 |
Cost recognized upon sale of acquired inventory | |
| (300) | |
| (1,512) |
Amortization of intangibles | |
| (19,283) | |
| (18,389) |
Acquisition related expenses | |
| (297) | |
| 2,377 |
Impact of partially owned-consolidated subsidiaries(1) | |
| 647 | |
| (1,562) |
Stock-based compensation, inclusive of employer taxes | |
| (15,458) | |
| (13,860) |
Restructuring costs | |
| (2,170) | |
| (1,185) |
Operating income | | $ | 56,317 | | $ | 63,222 |
1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party.
BIO-TECHNE CORPORATTON
RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA
(In thousands)
(Unaudited)
| QUARTER | ||||
| ENDED | ||||
| 9/30/2022 | | 9/30/2021 | ||
Net earnings attributable to Bio-Techne | $ | 89,555 | | $ | 69,615 |
Net interest expense (income) |
| 3,357 | |
| 3,216 |
Depreciation and amortization |
| 26,641 | |
| 24,734 |
Income taxes (benefit) |
| 13,982 | |
| (1,598) |
EBITDA |
| 133,535 | |
| 95,967 |
Costs recognized upon sale of acquired inventory |
| 300 | |
| 1,512 |
Acquisition related expenses |
| 678 | |
| (2,262) |
Gain on sale of partially owned consolidated subsidiaries |
| (11,682) | |
| — |
Stock-based compensation, inclusive of employer taxes |
| 15,458 | |
| 13,860 |
Restructuring costs |
| 2,170 | |
| 1,185 |
Investment (gain) loss and other |
| (38,087) | |
| (6,235) |
Impact of partially-owned consolidated subsidiaries(1) | | (420) | | | 1,562 |
Adjusted EBITDA | $ | 101,952 | | $ | 105,589 |
1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party.
BIO-TECHNE CORPORATION
CONDENSED CASH FLOW
(In thousands)
(Unaudited)
|
| QUARTER | ||||
| | ENDED | ||||
| | 9/30/2022 | | 9/30/2021 | ||
CASH FLOWS FROM OPERATING ACTIVITIES |
| |
|
| |
|
Net earnings | | $ | 89,734 | | $ | 68,981 |
Adjustments to reconcile net earnings to net cash provided by operating activities | |
|
| |
|
|
Depreciation and amortization | |
| 26,641 | |
| 24,734 |
Costs recognized on sale of acquired inventory | |
| 300 | |
| 1,512 |
Stock-based compensation expense | |
| 14,461 | |
| 11,737 |
Gain on sale of CCXI investment | | | (37,176) | | | (5,277) |
Fair value adjustment to available for sale investments | |
| (911) | |
| — |
Contingent consideration payments - operating | |
| — | |
| (3,300) |
Fair value adjustment to contingent consideration payable | |
| (100) | |
| (2,800) |
Gain on sale of Eminence | |
| (11,682) | |
| — |
Other operating activities | |
| (25,186) | |
| (47,153) |
Net cash provided by operating activities | |
| 56,081 | |
| 48,434 |
CASH FLOWS FROM INVESTING ACTIVITIES | |
|
| |
|
|
Additions to property and equipment | |
| (9,556) | |
| (6,070) |
Acquisitions, net of cash acquired | | | (101,184) | | | — |
Proceeds from sale of Eminence | |
| 17,824 | |
| — |
Proceeds from sale of CCXI investment | | | 73,219 | | | — |
Other investing activities | |
| 9 | |
| (1,050) |
Net cash provided by (used in) investing activities | |
| (19,688) | |
| (7,120) |
CASH FLOWS FROM FINANCING ACTIVITIES | |
|
| |
|
|
Cash dividends | |
| (12,545) | |
| (12,493) |
Proceeds from stock option exercises | |
| 11,950 | |
| 37,880 |
Long-term debt activity, net | |
| 8,661 | |
| (41,125) |
Contingent consideration payments - financing | |
| — | |
| (700) |
Share repurchases | |
| (19,562) | |
| — |
Other financing activities | |
| (20,310) | |
| (23,246) |
Net cash provided by (used in) financing activities | |
| (31,806) | |
| (39,684) |
Effect of exchange rate changes on cash and cash equivalents | |
| (11,897) | |
| (4,400) |
Net increase (decrease)in cash and cash equivalents | |
| (7,310) | |
| (2,770) |
Cash and cash equivalents at beginning of period | |
| 172,567 | |
| 199,091 |
Cash and cash equivalents at end of period | | $ | 165,257 | | $ | 196,321 |